---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010224"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T15:56:28.177052+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences raises $30.3M in PIPE financing with warrants for up to $92.4M more

## Summary
- Gross proceeds of $30.3M from sale of 9,757,669 common units at $2.15/unit and 4,371,027 pre-funded units at $2.14/unit.
- Each unit includes one common share (or pre-funded warrant) and Tranche A, B, and C warrants with exercise prices of $2.02, $2.02, and $2.50, respectively.
- Tranche A/B warrants subject to shareholder approval and expire upon 6-month or 12-month PMN310 data announcement; Tranche C expires July 31, 2029.
- Proceeds to advance clinical development of PMN310, an antibody for Alzheimer's disease, plus working capital and general expenses.
- All outstanding Series 2 Preferred Shares automatically convert into 1,166,667 common shares upon closing of this offering.

## SEC filing metadata
- accession: 0001558370-24-010224
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837024010224/0001558370-24-010224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837024010224/pmn-20240726x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010224
- JSON: https://secwatch.observer/filing/0001558370-24-010224.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.